吉非替尼作为二线及三线方案治疗晚期非小细胞肺癌疗效观察.doc

吉非替尼作为二线及三线方案治疗晚期非小细胞肺癌疗效观察[摘要] 目的 观察吉非替尼（易瑞沙）治疗非小细胞肺癌（NSCLC）复发转移患者的疗效及其毒副反应。方法 回顾性研究2007年2月～2010年2月我院各科治疗的非小细胞肺癌术后复发转移患者，分为A、B两组，A组以吉非替尼为二线治疗方案，B组以细胞毒药物作为二线方案而吉非替尼作为三线治疗方案，评价两组患者近期及远期的疗效。结果 吉非替尼作为二线治疗方案，其疾病控制率（CR+PR+SD）为73%，有效率（CR+PR）为59%，6个月生存率为86%，1年生存率为45%；作为三线治疗，疾病控制率（CR+PR+SD）为56%，有效率（CR+PR）为38%，6个月生存率为76%，1年生存率为28%。结论 对于转移复发非小细胞肺癌患者，尽早应用吉非替尼治疗可以使患者更大获益。 [关键词] 肿瘤；非小细胞肺癌；吉非替尼 [中图分类号] R734.2 [文献标识码] B[文章编号] 1673-9701（2011）21-71-03 The Observation of Therapeutic Effect of Gefitinib in Terminal NSCLC LIU Ke JIANG Xiangyang WANG Chao XIAO Xin Department of Oncology, the First People’s Hospital of Chaohu in Anhui Province, Chaohu 238000, China [Abstract] Objective To observe therapeutic effect of gefitinib（Iressa）as second-line and third-line treatment in patients with non-small cell lung cancer（NSCLC）recurrence and metastasis. Methods Retrospective studies were made on NSCLC cases treated in our hospital from February 2007 to February 2010. 51 patients were divided into A, B two groups. A group accepted the therapy of gefitinib as second-line treatment and B group accepted the therapy of cytotoxic drug as second-line treatment and gefitinib as third-line treatment. The short and long term effects were evaluated. Results In A group, disease control rate was 73%, effective rate was 59%，6-month survival rate was 86%, 1-year survival rate was 45%. In B group, disease control rate was 56%, effective rate was 38%，6-month survival rate was 76%, 1-year survival rate was 28%. Conclusion For non-small cell lung cancer with metastasis and recurrence in patients, earlier application of gefitinib therapy can benefit patients more. [Key words] Tumor; Non-small cell lung cancer; Gefitinib 肺癌是我国最常见的恶性肿瘤之一，其治疗也是目前肿瘤领域的研究热点之一，特别是晚期肺癌患者，尽管化疗方案不断更新，生存期却无显著延长[1]。研究显示化疗对晚期或复发肺癌的有效率仅为20%～40%，1年生存率仅35%～45%[2]。直到近年来分子靶向治疗为其拓展了新的治疗途径，不但取得了较好的疗效，而且也为化疗耐药或不能耐受化疗的患者提供了新的治疗方法，其中吉非替尼（易瑞沙）是最常见分子靶向药物之一，目前已被推荐为肺癌的二线及三线治疗药物[3-5]。我院2007年2月～2010年2月通过二线治疗组与三线治疗组的对照，评价吉非替尼作为二线方案及